News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,626 Results
Type
Article (43473)
Company Profile (347)
Press Release (668806)
Section
Business (211998)
Career Advice (2164)
Deals (37034)
Drug Delivery (103)
Drug Development (83940)
Employer Resources (173)
FDA (16611)
Job Trends (15528)
News (359220)
Policy (34334)
Tag
Academia (2608)
Alliances (51713)
Alzheimer's disease (1257)
Approvals (16531)
Artificial intelligence (145)
Bankruptcy (368)
Best Places to Work (11739)
Biotechnology (221)
Breast cancer (122)
Cancer (1117)
Cardiovascular disease (105)
Career advice (1802)
Cell therapy (242)
Clinical research (66661)
Collaboration (399)
Compensation (202)
COVID-19 (2625)
C-suite (97)
Data (1132)
Diabetes (162)
Diagnostics (6254)
Drug pricing (96)
Earnings (86936)
Employer resources (152)
Events (113494)
Executive appointments (316)
FDA (17151)
Funding (356)
Gene therapy (190)
GLP-1 (645)
Government (4512)
Healthcare (19000)
Infectious disease (2715)
Inflammatory bowel disease (112)
Interviews (337)
IPO (16731)
Job creations (4156)
Job search strategy (1549)
Layoffs (449)
Legal (8463)
Lung cancer (179)
Manufacturing (190)
Medical device (13310)
Medtech (13315)
Mergers & acquisitions (20364)
Metabolic disorders (449)
Neuroscience (1548)
NextGen Class of 2024 (6715)
Non-profit (4539)
Northern California (1486)
Obesity (260)
Opinion (222)
Patents (108)
People (58740)
Pharmaceutical (101)
Phase I (20717)
Phase II (29296)
Phase III (21955)
Pipeline (458)
Postmarket research (2673)
Preclinical (8769)
Radiopharmaceuticals (244)
Rare diseases (232)
Real estate (6349)
Regulatory (22694)
Research institute (2381)
Resumes & cover letters (370)
Southern California (1305)
Startups (3779)
United States (13640)
Vaccines (579)
Weight loss (208)
Date
Today (128)
Last 7 days (808)
Last 30 days (3795)
Last 365 days (36532)
2024 (33447)
2023 (40928)
2022 (52113)
2021 (56676)
2020 (55114)
2019 (47825)
2018 (36141)
2017 (33570)
2016 (33172)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30166)
2011 (30871)
2010 (28889)
Location
Africa (804)
Arizona (201)
Asia (40954)
Australia (6496)
California (3348)
Canada (1292)
China (252)
Colorado (145)
Connecticut (154)
Europe (87611)
Florida (461)
Georgia (116)
Illinois (349)
Indiana (206)
Maryland (585)
Massachusetts (2641)
Michigan (158)
Minnesota (273)
New Jersey (965)
New York (954)
North Carolina (741)
Northern California (1486)
Ohio (141)
Pennsylvania (843)
South America (1179)
Southern California (1305)
Texas (471)
Washington State (366)
712,626 Results for "lantern pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced that the Japan Patent Office has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma’s drug candidate LP-284.
June 12, 2024
·
8 min read
Press Releases
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
November 7, 2024
·
18 min read
News
Lantern Pharma to Host & Participate in Two Public Webinars During October
October 21, 2024
·
8 min read
Press Releases
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
October 23, 2024
·
5 min read
Business
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024.
May 9, 2024
·
20 min read
FDA
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
October 15, 2024
·
10 min read
Business
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
Lantern Pharma Inc. today announced that it will host its first quarter 2024 financial results webcast on Thursday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.
May 2, 2024
·
6 min read
Press Releases
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
November 19, 2024
·
7 min read
Drug Development
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Lantern Pharma Inc. announced today that – the company has received regulatory approval to expand its Harmonic™ trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer.
April 22, 2024
·
10 min read
Lone Star Bio
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
Lantern Pharma Inc. announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications.
May 6, 2024
·
15 min read
1 of 71,263
Next
